European Journal of Chemistry 2018, 9(3), 251-257. doi:10.5155/eurjchem.9.3.251-257.1731

Development of spectrofluorimetric stability indicating method for determination of naratriptan hydrochloride in pharmaceutical dosage form


Mohamed Rizk (1) orcid , Maha Sultan (2) orcid , Mona Elshahed (3) orcid , Mourad Ali (4,*) orcid

(1) Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, EinHelwan, 11795, Cairo, Egypt
(2) Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, EinHelwan, 11795, Cairo, Egypt
(3) Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, EinHelwan, 11795, Cairo, Egypt
(4) Analytical Chemistry Department, Faculty of Pharmacy, Helwan University, EinHelwan, 11795, Cairo, Egypt
(*) Corresponding Author

Received: 06 May 2018, Accepted: 29 Jun 2018, Published: 30 Sep 2018

Abstract


A stability indicating spectrofluorimetric method is developed for the determination of naratriptan hydrochloride in pharmaceutical formulation. The proposed method is based on investigation of the native fluorescence spectral behaviour of the drug in aqueous phosphate buffer (pH = 7.0±0.2).The fluorescence intensity is measured at 355.0 nm after excitation at 230.0 nm. The fluorescence-concentration plot is linear over the concentration range 8.0-80.0 ng/mL, with lower detection limit of 2.6 ng/mL and quantification limit of 7.6 ng/mL. The method is successfully applied to the analysis of the studied drug in its commercial tablet. Furthermore, the proposed method is applied in dissolution study of tablet; the results are in good agreement with those obtained with the reference method. The proposed method is approved to be a stability-indicating assay after exposure of the drug to different forced degradation conditions, such as acidic, alkaline and oxidative conditions, according to International Conference on Harmonization guidelines.


Keywords


Naredrix®; Dissolution studies ;Stability indicating; Spectrofluorimetry; Forced degradation; Naratriptan hydrochloride

Full Text:

PDF /    /


DOI: 10.5155/eurjchem.9.3.251-257.1731

Article Metrics


This Abstract was viewed 280 times | PDF Article downloaded 91 times

References

[1]. Moffat, A. C.; Osselton, M. D.; Widdop, B.; Watts, J. Clarke's analysis of drugs and poisons in pharmaceutical, body fluids and postmortem material, 4th Edition, Pharmaceutical Press, London, 2011.

[2]. The United States Pharmacopeia and National Formulary (USP 29-NF 24), 2006 Edition, pp. 1487-1488, 2006.

[3]. Sweetman, S., Martindale: The Complete Drug Reference, 36th edition, Pharmaceutical Press, London, 2009.

[4]. Velasco-Aguirre, C.; Alvarez-Lueje, A. Talanta 2010, 82, 796-802.
https://doi.org/10.1016/j.talanta.2010.05.058

[5]. Shelke, S.; Shahi, S.; Patil, V.; Kale, S. Asian J. Biomed. Pharm. Sci. 2015, 5, 36-39.

[6]. Swamy. G, K.; Kumar, J. M. R.; Rao, J. V. L. N. S.; Kumar, U. A. Indo Am. J. Pharm. Sci. 2011, 1, 253-256.

[7]. Borse, J. S.; Shirkhedkar, A. A. J. Appl. Pharm. Sci. 2012, 6, 227-229.

[8]. Reddy, R. B. D.; Charitha, A.; Sowjanya, G. N.; Kumar, G. S.; Gananadhamu, S.; Kishore, G. K.; Chaitanya, K. K. J. Glob. Trends Phar. Sci. 2013, 4, 1107-1110.

[9]. Prajapati, P. B.; Chotalia, J.; Bodiwala, K. B.; Marolia, B. P.; Shah, S. A. J. Chromatogr. Sci. 2016, 54, 1129-1136.
https://doi.org/10.1093/chromsci/bmw080

[10]. Ramu, G.; Babu, A. B.; Kumar, M. S.; Rambabu, C. Braz. J. Pharm. Res. 2012, 5, 2627-2630.

[11]. Dulery, B. D.; Petty, M. A.; Schoun, J.; David, M.; Huebert, N. D. J. Pharmaceut. Biomed. 1997, 15, 1009-1020.
https://doi.org/10.1016/S0731-7085(96)01955-3

[12]. Vishwanathan, K.; Bartlett, M. G.; Stewart, J. T. Rapid Commun. Mass Spectrom. 2000, 1, 168-172.
https://doi.org/10.1002/(SICI)1097-0231(20000215)14:3<168::AID-RCM861>3.0.CO;2-9

[13]. Yadav, M.; Patel, C.; Patel, M.; Mishra, T.; Singhal, P.; Shrivastav, P. S.; Baxi, G. A. J. Chromatogr. Sci. 2011, 49, 101-107.
https://doi.org/10.1093/chrsci/49.2.101

[14]. Challa, B. R.; Awen, B. Z. S.; Chandu, B. R.; Shaik, R. P. Braz. J. Pharm. Sci. 2011, 47, 13-22.

[15]. Wehry, E. L.; Settle, A. F. Handbook of Instrumental Techniques for Analytical Chemistry. Chapter 26, Molecular Fluorescence and Phosphorescence Spectrometry, Prentice Hall, New Jersey, USA, 1997.

[16]. Walash, M. I.; Belal, F.; El-Enany, N.; Eid, M.; El-Shaheny, R. N. J. Fluoresc. 2011, 21, 1659-1667.
https://doi.org/10.1007/s10895-011-0855-x

[17]. Walash, M. I.; Belal, F.; El-Enany, N.; Eid, M.; El-Shaheny, R. N. Luminescence 2011, 26, 670-679.
https://doi.org/10.1002/bio.1294

[18]. JASCO, Model FP-6200 Spectrofluorometer Instruction Manual, Ishikawa-Cho, Hachioji, Tokyo, Japan, 2000.

[19]. ICH Harmonized Tripartite Guideline Q2 (R1). Validation of analytical procedures: text and methodology, International Conference on Harmonization. Geneva, Switzerland; 2005.

[20]. Miller, J. N.; Miller, J. C. Statistics and chemometrics for analytical chemistry, 5th Edition, Pearson Education: England, 2005.


How to cite


Rizk, M.; Sultan, M.; Elshahed, M.; Ali, M. Eur. J. Chem. 2018, 9(3), 251-257. doi:10.5155/eurjchem.9.3.251-257.1731
Rizk, M.; Sultan, M.; Elshahed, M.; Ali, M. Development of spectrofluorimetric stability indicating method for determination of naratriptan hydrochloride in pharmaceutical dosage form. Eur. J. Chem. 2018, 9(3), 251-257. doi:10.5155/eurjchem.9.3.251-257.1731
Rizk, M., Sultan, M., Elshahed, M., & Ali, M. (2018). Development of spectrofluorimetric stability indicating method for determination of naratriptan hydrochloride in pharmaceutical dosage form. European Journal of Chemistry, 9(3), 251-257. doi:10.5155/eurjchem.9.3.251-257.1731
Rizk, Mohamed, Maha Sultan, Mona Elshahed, & Mourad Ali. "Development of spectrofluorimetric stability indicating method for determination of naratriptan hydrochloride in pharmaceutical dosage form." European Journal of Chemistry [Online], 9.3 (2018): 251-257. Web. 17 Sep. 2019
Rizk, Mohamed, Sultan, Maha, Elshahed, Mona, AND Ali, Mourad. "Development of spectrofluorimetric stability indicating method for determination of naratriptan hydrochloride in pharmaceutical dosage form" European Journal of Chemistry [Online], Volume 9 Number 3 (30 September 2018)

DOI Link: https://doi.org/10.5155/eurjchem.9.3.251-257.1731

Refbacks

  • There are currently no refbacks.




Copyright (c) 2018 Authors

Creative Commons License
This work is published and licensed by Atlanta Publishing House LLC, Atlanta, GA, USA. The full terms of this license are available at http://www.eurjchem.com/index.php/eurjchem/pages/view/terms and incorporate the Creative Commons Attribution-Non Commercial (CC BY NC) (International, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0). By accessing the work, you hereby accept the Terms. This is an open access article distributed under the terms and conditions of the CC BY NC License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited without any further permission from Atlanta Publishing House LLC (European Journal of Chemistry). No use, distribution or reproduction is permitted which does not comply with these terms. Permissions for commercial use of this work beyond the scope of the License (http://www.eurjchem.com/index.php/eurjchem/pages/view/terms) are administered by Atlanta Publishing House LLC (European Journal of Chemistry).


© Copyright 2019  Atlanta Publishing House LLC All Right Reserved.

The opinions expressed in all articles published in European Journal of Chemistry are those of the specific author(s), and do not necessarily reflect the views of Atlanta Publishing House LLC, or European Journal of Chemistry, or any of its employees.

Copyright 2019 Atlanta Publishing House LLC. All rights reserved. This site is owned and operated by Atlanta Publishing House LLC whose registered office is 4614 Lavista road, Tucker, GA, 30084, USA. Registered in USA.